Prevalent Drug Resistance Among Oral Yeasts from Asymptomatic Patients in Hainan, China
The oral cavity is a significant niche of the human microbiome and a gateway for the microbiota in many other human body sites. As a result, understanding the oral microbiota has broad implications for the prevention and management of human infectious diseases. Opportunistic yeast infections are among the most prevalent fungal infections of humans, and most opportunistic yeast pathogens are common residents of the oral mucosa. However, relatively little is known about the drug susceptibility profiles of oral yeasts. Here, we report the species distribution and patterns of antifungal susceptibility profiles among 313 yeasts isolated from the oral cavities of 301 asymptomatic hospitalized patients in Hainan Province in southern China. These yeasts were tested for their susceptibilities to the following five drugs: amphotericin B, fluconazole, itraconazole, ketoconazole, and fluorocytosine. Since none of the sampled hosts had taken any antifungal drugs at least 3 months before samples were taken, we hypothesized that little or no drug resistance should be observed. Contrary to our expectations, our analyses identified that 29 % (91/313) of the isolates were resistant to at least one drug and 14.3 % (45/313) were resistant to two or more of the five common drugs. The potential sources of the observed resistance were discussed.
KeywordsAntifungal resistance Oral yeasts Candida Geographic differences Origin of drug resistance
We thank the following people for helping with our sample collections: Leilei ZHANG, Fei LIU, and Yue DONG. Financial support for this project came from the Hainan Provincial Key Science Project (Grant numbers 090214 and 801010); the Department of Education of Hainan Province (Hjkj2012-36); and a training grant from Hainan Medical College (HY2010-009).
- 1.Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med 2012; 4:165rv13.Google Scholar
- 4.Odds FC. Candida and candidosis. London: Bailliere Tindall; 1988.Google Scholar
- 5.Pfaller MA, Moet GJ, Meser SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2011;55:561–6.PubMedCentralPubMedCrossRefGoogle Scholar
- 6.Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller TM. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from, 2008 to 2011. J Clin Microbiol. 2012;50:3435–4342.PubMedCentralPubMedCrossRefGoogle Scholar
- 9.Pemán J, Cantón E, Linares-Sicilia MJ, Roselló EM, Borrell N, Ruiz-Pérez-de-Pipaon MT, Guinea J, García J, Porras A, García-Tapia AM, Pérez-Del-Molino L, Suárez A, Alcoba J, García-García I. Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. J Clin Microbiol. 2011;49:4158–63.PubMedCentralPubMedCrossRefGoogle Scholar
- 11.Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571–81.PubMedCentralPubMedCrossRefGoogle Scholar
- 12.Bonfietti LX, Szeszs MW, Chang MR, Martins MA, Pukinskas SR, Nunes MO, Pereira GH, Paniago AM, Purisco SU, Melhem MS. Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital. Mycopathologia. 2012;174:389–96.PubMedCrossRefGoogle Scholar
- 14.Nelson KE, Madupu R, Szpakowski S, Goll JB, Krampis K, Methe BA. Next-generation sequencing, metagenomes, and the human microbiome. In Xu J editor. Next-generation sequencing: current technologies and applications. Norfolk: Caister Academic Press, pp. 141–155.Google Scholar
- 21.Schoch CL, and the Fungal Barcode Consortium. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci USA 2012; 109:6241–6246.Google Scholar
- 22.Luo C, Feng L, Dai HZ. Application of antifungal agents in 6 cities along the Yangzi River from 2005 to 2007. Chin J New Drugs Clin Remedies. 2009;10:785–90.Google Scholar
- 23.Li J. Analysis for usage of antifungal drugs from outpatient pharmacy. Strait Pharm J. 2012;24:258–9.Google Scholar
- 24.Institute CaLS. M44-A2 Reference method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline, second edition. Clinical and Laboratory Standards Institute. Wayne, PA. 2009.Google Scholar
- 25.Anonymous. NEO-SENSITABS User’s guide in antifungal susceptibility testing of yeast, Rosco Diagnóstica A/S, Denmark. 2011.Google Scholar
- 26.Sokal RR, Rohlf FJ. Biometry: the principles and practices of statistics in biological research. 2nd ed. New York: Freeman and Company; 1981.Google Scholar
- 27.Wu CJ, Lee HC, Yang YL, Chang CM, Chen HT, Lin CC, Lee NY, Chu WL, Hsieh LY, Wang YL, Lauderale TL, Tseng FC, Ko NY, Ko WC, Lo HJ. Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter. Clin Microbiol Infect. 2012;18:485–90.PubMedCrossRefGoogle Scholar
- 31.Zhang WJ, Jiang FB, Ou JF. Global pesticide consumption and pollution: with China as a focus. Proc Intl Acad Ecol Environ Sci. 2011;1:125–44.Google Scholar
- 32.Chowdhary A, Kathuria S, Xu J, Sharma C, Sundar G, Singh PK, Gaur SN, Hagen F, Klaassen CH, Meis JF. Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR34/L98H mutations in the cyp51A gene in India. PLoS ONE. 2012;7:e52871.PubMedCentralPubMedCrossRefGoogle Scholar
- 34.Anonymous. Market analyses of antifungal drugs. Guangzhou Pharmaceutical Info Limited (www.menet.com.cn). Guangzhou, China. 2011.